Loading clinical trials...

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

NCT06958861•Shanghai Huilun Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects must meet all of the following criteria to be eligible for enrollment in this study:
•1. Age ≥18 years, regardless of gender;
•2. Patients who are determined by the investigator to be in an acute exacerbation phase of bronchiectasis prior to enrollment: at least three out of the following six symptoms-cough, changes in sputum volume, purulent sputum, dyspnea or reduced exercise tolerance, fatigue or malaise, hemoptysis-have worsened for more than 48 hours, and the clinician deems that intervention is necessary;
•3. Able to tolerate nebulized inhalation treatment;
•4. After instruction, able to correctly use the nebulizer for treatment and accurately complete questionnaires;
•5. Subjects must fully understand the purpose, nature, methods, and potential adverse events of the trial, voluntarily agree to participate, and sign the informed consent form, or have a legally authorized representative provide informed consent on their behalf.

Exclusion Criteria

•1. Patients with bronchiectasis caused by cystic fibrosis, as determined by the investigator;
•2. Patients who have experienced an acute exacerbation of bronchiectasis for more than 7 days;
•3. Patients with an acute exacerbation of bronchiectasis who have received intravenous antibiotic treatment for more than 72 hours prior to enrollment;
•4. Patients with mild bronchiectasis caused by asthma;
•5. Patients with comorbid allergic bronchopulmonary aspergillosis, active tuberculosis, or active non-tuberculous mycobacterial infection requiring standardized treatment;
•6. Patients with moderate or massive hemoptysis during an acute exacerbation of bronchiectasis (moderate hemoptysis: 100-500 mL within 24 hours; massive hemoptysis: \>500 mL within 24 hours or a single episode of 100-500 mL);
•7. Patients with significant liver or kidney dysfunction (ALT, AST \>2 times the upper limit of normal \[ULN\]; Cr \>1.5 times ULN);
•8. Patients with a history of malignancy or who have achieved clinical remission for less than 5 years;
•9. Patients with any other unstable clinical conditions deemed significant by the investigator, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physiological dysfunction, and: a) Whose condition may affect the patient's safety during the study; b) That may impact the study results and their interpretation; c) That may hinder the patient's ability to complete the entire study;
•10. Patients who are positive for hepatitis B surface antigen (HBsAg) with HBV-DNA \>1000 copies/mL or 200 IU/mL, or positive for hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or anti-Treponema pallidum antibody;
+4 more criteria

Locations (19)

Fuyang Hospital Of Anhui Medical University

Fuyang, Anhui, China

Hefei First People's Hospital

Hefei, Anhui, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

Affiliated hospital of Youjiang Medical University For Nationalities

Baise City, Guangxi, China

Hebei General Hospital

Shijiazhuang, Hebei, China

Nanyang Second General Hospital

Nanyang, Henan, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Yichang Central People's Hospital

Yichang, Hubei, China

Key Dates

Start Date

May 1, 2025

Primary Completion Date

May 1, 2027

Completion Date

May 1, 2027

Last Updated

May 9, 2025

Enrollment

180

ESTIMATED participants

Conditions

Acute Exacerbations of Bronchiectasis

Interventions

Low-dose H057+standard-of-care

DRUG

High-dose H057+standard-of-care

DRUG

H057 placebo+standard-of-care

DRUG

Contacts

Zhanyang Zhu

CONTACT

86-021-64311017 clinical_trial@hllife.com.cn